Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Open Angle Glaucoma
Interventions: Acular LS, Pred Forte, Refresh Tears; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertension
Interventions: AI-Driven Lifestyle Coaching Program; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ocular Hypertension
Interventions: Scleral Lens; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes, Hypertension
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Remote Visit; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions: PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Artesia, California • Newport Beach, California • Petaluma, California + 15 more

Conditions: Hypertension
Interventions: Home Blood Pressure Monitoring; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pseudotumor Cerebri, Cystinosis
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Darusentan, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more

Conditions: Hypertension (HTN)
Interventions: Firibastat (QGC001) Period 1; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: HIV Infection, Pulmonary Hypertension, Endothelial Function, HIV Infections
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Nanodropper adaptor, control; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension
Interventions: Spironolactone, Chlorthalidone, Diet, Placebo; Drug · Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: Personal Health Record; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost, Latanoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Kidney Transplant; Complications, Kidney Diseases, Transplant;Failure,Kidney, Diabetes, Hypertension, Obesity, Diet, Healthy, Lifestyle, Healthy
Interventions: Dietary Education Curriculum; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Atrial Fibrillation (AF), Hypertension (HTN), High Blood Pressure
Interventions: Blood Pressure Monitor Without AFib Detection, Blood Pressure Monitor With AFib Detection; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 1,910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions: No Intervention; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 20 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease
Interventions: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 79 Years
Enrollment: 7,287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more

Conditions: Pre-hypertension
Interventions: Tension Tamer (TT), Lifestyle education program (SPCTL); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Heart Failure, Congestive and Microalbuminuria
Interventions: metoprolol xl, carvedilol MR, lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more

Conditions: Prehypertension
Interventions: Marealis refined peptide concentrate, Placebo; Dietary Supplement
Lead sponsor: KGK Science Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Addison, Illinois

Search by objective public record fields.

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

An Artificial Intelligence-Assisted Digital Health Lifestyle Intervention for Adults With Hypertension

Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Remote Physician Care for Home Hospital Patients

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Home Blood Pressure Monitoring Project

The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Tissue Sodium in Pre-hypertensive Patients

Insights for Community Health

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Dietary Intervention to Improve Kidney Transplant Outcomes

Out-of-office Monitoring for Rhythms Of Normal Versus Atrial Fibrillation

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Intensive Glycemic Control and Skeletal Health Study

Tension Tamer Randomized Control Trial

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects